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ﬁnd increased numbers of FOXP3pos cells within the inﬂamma-
tory inﬁltrate of patients with AIH. In our study, FOXP3pos cells
were detected in most liver biopsies from AIH patients, but they
represented a small component of the portal tract inﬂammatory
inﬁltrate. No comparison was made with normal or pathological
control livers. As FOXP3pos cells are reportedly absent or scarce in
the normal liver, when tested by immunohistochemistry [6,7], it
can be argued that we did ﬁnd increased numbers of tissue
FOXP3pos cells in AIH. In support of their ﬁndings, Peiseler et al.
refer to Buckner’s review [5], which quotes increased numbers
of tissue FOXP3pos cells in human autoimmune disease, such as
in the skin in psoriasis and in the gut in inﬂammatory bowel
disease. Interestingly, in the same review [5] Treg function is
documented to be decreased in most human autoimmune
diseases, including type 1 diabetes, multiple sclerosis, systemic
lupus erythematosus, rheumatoid arthritis and psoriasis, in
agreement with what reported by us [4] and others [2,3] in AIH.
Of note, a numerical defect of peripheral Tregs has been
reported in primary biliary cirrhosis (PBC), another autoimmune
liver disease [6]. In the same paper, the frequency of FOXP3pos
cells within the CD3pos liver inﬁltrating T lymphocytes was
approximately 12% in PBC, 18% in AIH, and 28% in chronic hepa-
titis C [6], though a more recent paper by Oo et al. has reported a
frequency of about 12% in both AIH and PBC [7]. As acknowledged
by Peiseler et al. [1] and Bukner [5], the use of FOXP3 as sole mar-
ker of Tregs in tissues is inadequate, FOXP3 being also expressed
by effector T cells following activation [5]: more accurate infor-
mation will be obtained when better markers for immunohisto-
chemical detection of Tregs become available.
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JOURNAL OF HEPATOLOGYTo the Editor:
We read with interest the comment by Ferri et al. to our paper
on Tregs in autoimmune hepatitis (AIH) [1], in which they
emphasise several discrepancies between their recently pub-
lished ﬁndings [2] and ours. Ferri et al. explain these discrepan-
cies by methodological differences; however, ﬁnd it difﬁcult to
compare the methodologies. We are grateful for the opportunity
to clarify our methodology in comparison to that used by Ferri
et al.
(1) Ferri et al. report that the frequency of CD4+CD25high-
FOXP3+ cells ‘‘is markedly reduced in AIH compared to
healthy subjects’’, whereas we ﬁnd that the frequency of
CD4+CD25(high)CD127(low)FOXP3+ in blood of AIH
patients was not reduced compared to healthy subjects.
To determine the Treg frequency in peripheral blood, Ferri
et al. ﬁrst puriﬁed CD4+CD25+ lymphocytes from periphe-
ral blood by a two-step magnetic puriﬁcation procedure,
i.e. depletion of non-CD4 cells followed by enrichment of
CD25+ cells. Only then, the percentage of FOXP3+ cells inJournal of Hepatology 2012 vothe isolated subgroup of blood cells was determined. In
contrast, we did not isolate a subfraction of cells from
peripheral blood, but instead performed a direct ex vivo
analysis of unfractionated peripheral blood cells by stain-
ing for CD4, CD25, FOXP, and CD127. The gating strategy
for this analysis is actually shown in Fig. 1A of our paper.
We see at least two critical advantages of our approach:
ﬁrst, by direct ex vivo analysis, we avoid the potential
selection bias that is inevitable when performing a sub-
fraction analysis after an enrichment procedure; second,
by including CD127 as an additional marker, we greatly
increase the ﬁdelity of Treg identiﬁcation. Moreover, we
conﬁrmed the ﬁndings obtained by this method with
another method, i.e. analysis of the FOXP3 TSDR DNA
methylation status.
2) Ferri et al. ﬁnd a ‘‘defective ability of Treg cells to control the
proliferation of CD4+CD25- target cells’’; while we do not
ﬁnd a reduced suppressor function of Treg from AIH
patients. To determine Treg suppressor function, Ferri et
al. used the 3H-thymidine assay; we, in contrast, usedl. 57 j 1152–1159 1155
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the CFSE assay. The critical advantage of the CFSE assay
over the 3H-thymidine assay is its substantially higher sig-
nal to noise-ratio [3–6]. For the full argument on why the
CFSE assay is much more meaningful than the 3H-thymi-
dine assay, we refer to Sakaguchi et al. [3] who summarise
‘‘that thymidine uptake by cultured Treg and effector cells is
not appropriate to assess suppressive activity of human Treg
cells’’, and instead ‘‘propose that it is more accurate to assess
dilution of CFSE in effector T cells to determine the percentage
and number of proliferating cells’’.
(3) We read with great surprise the remark by Ferri et al. that,
for performing the CFSE assay, we did not provide data ‘‘to
assess the efﬁciency of the puriﬁcation’’ or whether the ‘‘puri-
ﬁed cells are CD127low’’. In contrast to Ferri et al., who did
not analyse the CD127 status of the puriﬁed cells, we did
characterise both the puriﬁed Treg cells and the puriﬁed
non-Treg cells for expression of CD127. This was clearly
stated in our paper and a representative analysis of FOXP3
and CD127 status of the puriﬁed cells is shown in Fig. 2A of
our paper.
(4) Ferri et al. criticise the fact that we used a Treg/T
effector ratio of 1:1 in our suppressor assay, which is not
supposed to reﬂect the Treg frequency in peripheral blood.
However, the Treg frequency in blood is irrelevant for
their suppressor function. Treg cells do not suppress on
the ﬂy while ﬂowing with the blood stream; they suppress
mainly through cell contact between one cell and another
within (lymphoid) tissues. Consequently, as others have
shown [4–6], the suppressive potential of Treg cells can
be reasonably assessed with the CFSE assay at a ratio of
1:1.
(5) Ferri et al. reported the presence of FOXP3+ cells in the liv-
ers of 5/7 AIH patients, but did not make a comparison
with other inﬂammatory liver diseases. We ﬁnd that the
numbers of FOXP3+ cells were signiﬁcantly higher in AIH
livers than in NASH livers, and that the number of FOXP3+
cells in the liver correlated with histological disease
activity.Mid-regional pro-adrenomedu
better prognostic biomarker tha
short-term survival in pati
cirrhosis at risk
To the Editor:
We read with great interest the study by Cervoni et al. [1]
investigating C-reactive protein (CRP) as a prognostic marker of
short-term mortality in patients with advanced cirrhosis.
Although persistently elevated CRP levels discriminated patients
with poor prognosis due to presumably ongoing systemic inﬂam-
mation, in their study, baseline CRP was less accurate discrimi-
nating bacterial infection and its hemodynamic and renal
complications, which substantially contribute to the increased
mortality in patients with cirrhosis and might be discriminated
using novel biomarkers. A candidate biomarker is the mid-regio-
1156 Journal of Hepatology 20In summary, we have reasons to believe that the methodology
used by us was appropriate and that the conclusions drawn from
these experiments are valid.
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nal fragment of pro-adrenomedullin (MR-proADM), which has
been demonstrated to be an excellent predictor of short-term
mortality in patients with sepsis [2], lower respiratory tract infec-
tions [3] and critically ill patients with new-onset fever [4].
MR-proADM is the non-functional, more stable precursor pep-
tide of adrenomedullin, a vasoactive calcitonin peptide family
member that is rapidly cleared from circulation [5]. Circulating
adrenomedullin mainly originates from endothelial cells and
vascular smooth muscle cells and is upregulated under inﬂam-
matory stimuli mediated by pro-inﬂammatory cytokines or bac-
terial endotoxin, under hypervolemia and during tissue hypoxia
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